News and Trends 6 Mar 2025
Top biotech deals of February 2025
Find out about the top biotech partnership deal of February 2025. Small molecules, T-cell engagers, and RNA medicines, were all part of major collaborations.
- Latest Posts
Best in Biotech 5 Mar 2025
Seven biotech companies keeping Taiwan dynamic in 2025
Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development, backed by strong research and government support.
In Depth 4 Mar 2025
The biggest biotech funding rounds in February 2025
The companies Eikon Therapeutics, Sionna Therapeutics, and Abcuro bagged the biggest biotech funding rounds overall in February 2025.
R&D trends: Biotech assets & discovery platforms
Inpart’s latest report provides access to the most promising biotech assets and discovery platforms, shedding light on the latest trends in biotech R&D.
Best in Biotech 28 Feb 2025
Rare Disease Day: seven drugs awaiting approval in 2025
As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in 2025.
Podcast 28 Feb 2025
The TCR-T cell therapies of tomorrow
Sweden’s fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with TCR-T cell therapy trials.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 27 Feb 2025
Eight respiratory disease companies advancing innovative therapies in 2025
Discover eight respiratory disease companies advancing their novel therapies through clinical trials in 2025.
In Depth 26 Feb 2025
New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?
Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis.
Best in Biotech 25 Feb 2025
Seven biotech spinouts to watch out for in 2025
Here are seven biotech spinouts to keep an eye out for this year that specialize in a number of therapeutic areas.
How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases
Find out how the virtual biotech company Libra Therapeutics leveraged data to accelerate drug development for neurodegenerative diseases.
News and Trends 24 Feb 2025
Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?
This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues.
In Depth 21 Feb 2025
The future of organ transplants: Xenotransplantation, 3D bioprinting and stem cells
Discover how biotech could solve the organ shortage crisis through xenotransplantation, 3D bioprinting and stem cells.
ADVERTISEMENT
